News for Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans, Actinium Pharmaceuticals, Inc. (NYSE:ATNM) showcased promising preclinical results for its prostate cancer candidate, ATNM-400. The data indicated that the leading drug demonstrated superior […]

Actinium Pharmaceuticals (ATNM) recently unveiled compelling preclinical findings for its innovative prostate cancer therapy, ATNM-400, at the Society of Nuclea

PR NewswireNEW YORK, June 10, 2025 NEW YORK, June 10, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether cer

PR NewswireNEW YORK, May 26, 2025 NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Actiniu

PR NewswireNEW YORK, May 26, 2025 NEW YORK, May 26, 2025 /PRNewswire/ --

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Actinium To Contact Him Dir...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Actinium To Contact Him Dir...

PR NewswireNEW YORK, May 22, 2025 NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmac

PR NewswireNEW YORK, May 21, 2025 NEW YORK, May 21, 2025 /PRNewswire/ --

PR NewswireNEW YORK, May 19, 2025 NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmac

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Actinium To Contact Him Dir...

PR NewswireNEW YORK, May 16, 2025 NEW YORK, May 16, 2025 /PRNewswire/ --

PR NewswireNEW YORK, May 12, 2025 NEW YORK, May 12, 2025 /PRNewswire/ --

PR NewswireNEW YORK, May 12, 2025 NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Actiniu

On May 12, 2025, Actinium Pharma (ATNM) received attention from HC Wainwright & Co., as analyst Joseph Pantginis reiterated a 'Buy' rating for the company. The

PR NewswireNEW YORK, May 12, 2025 NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmac

NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to l...

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (”œActin

Actinium Pharmaceuticals (ATNM) has initiated a significant clinical trial involving their Iomab-ACT targeted conditioning agent. The first patient has been enr